Sökning: id:"swepub:oai:DiVA.org:uu-297969"
> (2016) >
Cost-effectiveness ...
-
Verhoef, T. I.UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands
(författare)
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden
- Artikel/kapitelEngelska2016
Förlag, utgivningsår, omfång ...
-
2016-06-07
-
Springer Science and Business Media LLC,2016
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-297969
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-297969URI
-
https://doi.org/10.1038/tpj.2016.41DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:134296824URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were £26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were £6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of £20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Redekop, W. K.Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
(författare)
-
Langenskiöld, SophieUppsala universitet,Hälsoekonomi,Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden(Swepub:uu)sopla565
(författare)
-
Kamali, F.Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
(författare)
-
Wadelius, MiaUppsala universitet,Klinisk farmakogenomik och osteoporos,Science for Life Laboratory, SciLifeLab(Swepub:uu)miawadel
(författare)
-
Burnside, G.Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England
(författare)
-
Maitland-van der Zee, A-H.Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands
(författare)
-
Hughes, D. A.Bangor Univ, Ctr Hlth Econ & Med Evaluat, Bangor, North Wales, Wales
(författare)
-
Pirmohamed, M.Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England
(författare)
-
UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, NetherlandsErasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:The Pharmacogenomics Journal: Springer Science and Business Media LLC16:5, s. 478-4841470-269X1473-1150
Internetlänk
Hitta via bibliotek
Till lärosätets databas